TARGETING OF INFLAMMATORY MONOCYTES VIA CCL2/CCR2 SIGNALING AS A THERAPEUTIC STRATEGY AGAINST AUTOIMMUNE HEPATITIS BY USING MACROPHAGE-DERIVED EXTRACELLULAR VESICLES

<div><p><b>Background: </b>Autoimmune hepatitis is a serious chronic liver disease with immune disorders, histological lesions and liver dysfunction, with a gradually increasing prevalence. Yet the cellular and molecular mechanisms of immune dysregulation in AIH are poorly understood.</p>

DEEP PHENOTYPING OF TM6SF2 TO CHARACTERIZE HEPATIC STEATOSIS, PLASMA LIPID TRAITS, AND METABOLIC RISK FACTORS USING A GENOME-FIRST APPROACH

<div><p><b>Background: </b>An unbiased ‘genome-first’ approach has the potential to expand the understanding of common coding and predicted loss-of-function (pLOF) variants associated with non-alcoholic fatty liver disease (NAFLD). Utilizing this approach, we aimed to uncover the functionality of pathogenic variants in <em>TM6SF2</em>.</p>

ANALYSIS OF IMMUNE-RELATED ADVERSE EVENTS AND TIME-TO-TREATMENT DISCONTINUATION OF ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTICENTER COHORT STUDY

<div><p><b>Background:</p> </b><p>Pragmatic endpoints, such as time-to-treatment discontinuation (TTD), defined as the duration from starting a medication to the date of treatment discontinuation or death, have been proposed as a potential efficacy endpoint for real-world practice. This study aims to analyze the frequency and severity of immune-related adverse events (irAEs) and TTD in patients with hepatocellular carcinoma (HCC) receiving Atezolizumab and Bevacizumab (A+B) treatment.</p>

DAILY ASPIRIN THERAPY FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL

<div><p><b>Background: </b>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic, progressive disease with substantial morbidity and mortality and no approved treatments. Observational studies have linked aspirin use to reduced prevalence and progression of MASLD. However, the efficacy and safety of aspirin for reducing hepatic steatosis, inflammation, and fibrosis in patients with MASLD are unknown.</p>

MITOCHONDRIAL Ca2+ UNIPORTER (MCU) IN HEPATOCYTES BUT NOT IN KUPFFER CELLS PROMOTES LIVER INJURY INDUCED BY ACETAMINOPHEN (APAP)

<div><p><b>Background: </b>Iron-catalyzed formation of reactive oxygen species (ROS) increases after APAP overdose and triggers the mitochondrial permeability transition (MPT). Previous studies show that iron translocation from lysosomes into mitochondria by MCU in hepatocytes promotes the MPT after APAP. Kupffer cells are liver resident macrophages that are involved in uptake, processing, and export of iron. Here, our Aim was to investigate and compare the roles of MCU in hepatocytes and Kupffer cells in APAP hepatotoxicity. </p>

HUMAN-CORRELATED GENETIC HCC MODELS IDENTIFY COMBINATION THERAPY FOR PRECISION MEDICINE

<div><p><b>Background:</p> </b><p>Hepatocellular carcinoma (HCC) is a major cause of mortality worldwide. Providing precision medicine to patients is a key unmet need. Preclinical models, when accurately reflecting human disease, offer an opportunity to understand varying therapeutic responses between different patient groups.</p>

PRELIMINARY OFF-TREATMENT RESPONSES FOLLOWING 48 WEEKS OF VEBICORVIR, NUCLEOS(T)IDE REVERSE TRANSCRIPTASE INHIBITOR, AND AB-729 COMBINATION IN VIROLOGICALLY SUPPRESSED PATIENTS WITH HEPATITIS B E ANTIGEN NEGATIVE CHRONIC HEPATITIS B: ANALYSIS FROM AN OPEN

<div><p><b>Background:</p> </b><p>This open-label study assessed the safety and efficacy of vebicorvir (VBR)+AB-729+nucleos(t)ide reverse transcriptase inhibitor (NrtI) in virologically suppressed (VS) patients (pts) with hepatitis B e antigen (eAg) negative chronic hepatitis B infection (NCT04820686). VBR is a 1st-generation core inhibitor and AB-729 is a single trigger GalNAc-siRNA targeting all HBV RNA transcripts. Initial end of treatment (EOT) responses were previously described.

SPIRONOLACTONE THERAPY ASSOCIATES WITH REDUCED INCIDENT ALCOHOL-ASSOCIATED LIVER DISEASE IN HIGH RISK PATIENTS: A RETROSPECTIVE COHORT STUDY

<div><p><strong><b>Background:</strong> </b><span class="NormalTextRun SCXW91602795 BCX0">Effective treatment for alcohol use disorder (AUD) is the cornerstone of preventing the development of alcohol-associated liver disease (ALD).

RISK OF ADVERSE LIVER AND RENAL OUTCOMES AFTER INITIATION OF A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR VS. GLP-1 RECEPTOR AGONISTS AND DIPEPTIDYL PEPTIDASE-4 INHIBITORS AMONG US ADULT PATIENTS WITH TYPE 2 DIABETES AND MASLD

<div><p><b>Background: </b>The effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on liver and renal outcomes in patients with type 2 diabetes mellitus (T2DM) were demonstrated in recent trials. However, the magnitude of benefits associated with underlying metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. We aimed to explore the risk of adverse liver and renal outcomes in patients with MASLD and T2DM taking SGLT-2i vs.

SLC1A5 REGULATES LIPID METABOLISM AND FORMS AN IMMUNOSUPPRESSIVE TME IN HCC

<div><p><b>Background: </b>Tumor microenvironment(TME) reflects the intertwined crosstalk between cancer cells and tumor-infiltrating immune cells, affecting the efficiency of immunotherapy. Metabolic reprogramming, one of the major hallmarks of hepatocellular carcinoma(HCC), is unclear in the aspect of reshaping TME. In this study, we report the vital role of SLC1A5, the major glutamine transporter of tumor cells, in HCC progression and the formation of immunosuppressive TME.</p>

Subscribe to